AZ opens drug portfolio to academic investigators

AstraZeneca ($AZN) and the Medical Research Council in the U.K. have come up with a new approach to rope in some fresh thinking on new uses for their compounds. AZ will let academic researchers ponder new approaches for 22 of their compounds, with the MRC chipping in up to £10 million to finance the work. Both groups say the public-private initiative promises to spur faster development efforts. "We hope that in sharing these valuable compounds with academic scientists through the MRC, new discoveries will be made by exploring additional uses of these compounds," says AstraZeneca CEO David Brennan. Release

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.